Phase Ib trial shows promising signs for colorectal cancer treatment

This prospective clinical trial examined a sequential combination of stereotactic body radiotherapy, pembrolizumab, and surgery. The study involved 15 subjects with oligometastatic colorectal cancer, drawn from a larger group of 243 patients across various stages. The team looked at how the treatment affected the immune system and whether it kept cancer from coming back. The main goal was to see if patients could stay free from recurrence for one year. The study met this primary endpoint, with 60% of patients achieving recurrence-free survival at the one-year mark. Researchers also found that a specific immune profile, called VPP, was present in 40% of the enrolled subjects. In these patients, the treatment further enhanced immune function. All patients in this specific subgroup were still alive at the time of the report. The trial was designed to be safe, and no serious adverse events or discontinuations were reported. Because this is a Phase Ib trial, the results are early and limited to a small group. Readers should view these findings as promising but not yet proven for widespread use.